27,889 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Vident Advisory LLC

Key Points

• Vident Advisory LLC has acquired a new position in Hims & Hers Health, purchasing 27,889 shares worth approximately $824,000 in the first quarter.
• Hims & Hers Health reported a 72.6% increase in revenue year-over-year for the last quarter but fell short of earnings expectations with $0.17 EPS compared to the estimated $0.18.
• Insider transactions showed significant sales, with a total of 1,390,328 shares sold by insiders in the last 90 days, representing a combined value of $71,468,298.

Vident Advisory LLC bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 27,889 shares of the company's stock, valued at approximately $824,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Signaturefd LLC increased its holdings in Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after buying an additional 388 shares during the last quarter. GAMMA Investing LLC increased its holdings in Hims & Hers Health by 128.5% in the first quarter. GAMMA Investing LLC now owns 5,143 shares of the company's stock worth $152,000 after buying an additional 2,892 shares during the last quarter. New York State Teachers Retirement System increased its holdings in Hims & Hers Health by 95.2% in the first quarter. New York State Teachers Retirement System now owns 194,795 shares of the company's stock worth $5,756,000 after buying an additional 94,983 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Hims & Hers Health in the fourth quarter worth approximately $1,230,000. Finally, Fifth Third Bancorp increased its holdings in Hims & Hers Health by 165.4% in the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock worth $46,000 after buying an additional 961 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $45.06, for a total value of $5,773,402.62. Following the transaction, the chief executive officer owned 89,521 shares of the company's stock, valued at approximately $4,033,816.26. This represents a 58.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $43.69, for a total value of $505,973.89. Following the transaction, the chief financial officer owned 116,806 shares of the company's stock, valued at $5,103,254.14. The trade was a 9.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,390,328 shares of company stock worth $71,468,298 over the last 90 days. Insiders own 17.71% of the company's stock.

Hims & Hers Health Price Performance

NYSE:HIMS traded up $1.93 during trading hours on Monday, reaching $50.34. The company had a trading volume of 12,710,215 shares, compared to its average volume of 33,066,438. The stock has a 50-day moving average of $50.03 and a two-hundred day moving average of $45.10. Hims & Hers Health, Inc. has a one year low of $13.70 and a one year high of $72.98. The firm has a market capitalization of $11.38 billion, a PE ratio of 62.60, a PEG ratio of 3.27 and a beta of 2.14. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same quarter last year, the company earned $0.06 earnings per share. The business's revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Citigroup restated a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Wall Street Zen cut Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Zacks Research cut Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Finally, Truist Financial decreased their target price on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research report on Monday, August 18th. Two investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Reduce" and an average target price of $38.92.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.